Comparative in Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus Pneumoniae Isolates from France

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2003 Aug 28

PMID 12942341

Citations 1

Authors

J W Decousser

P Pina

F Picot

P Y Allouch

Affiliations

Soon will be listed here.

Abstract

The aim of the study presented here was to evaluate the in vitro activity of faropenem, a new member of the penem class intended for oral administration, compared with 11 other antimicrobial agents against a large number of Streptococcus pneumoniae strains isolated from adults and children with bloodstream infections in France. The minimum inhibitory concentration of faropenem against 90% of the pediatric strains tested was generally one to two dilutions lower than the most potent beta-lactam agents (i.e., 0.5 micro g/ml for faropenem vs. 1 for amoxicillin, 1 for cefotaxime and 0.5 micro g/ml for ceftriaxone). Against the adult strains, only moxifloxacin had a MIC(90) value similar to faropenem (i.e., 0.25 micro g/ml for both agents). Faropenem seems to be a promising antimicrobial agent for the treatment of adult and pediatric Streptococcus pneumoniae infections.

Citing Articles

Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Abgueguen P, Azoulay-Dupuis E, Noel V, Moine P, Rieux V, Fantin B Antimicrob Agents Chemother. 2006; 51(1):208-14.

PMID: 17060515 PMC: 1797644. DOI: 10.1128/AAC.00004-06.

References

Spangler S, Jacobs M, Appelbaum P . In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime,.... Antimicrob Agents Chemother. 1994; 38(12):2902-4. PMC: 188304. DOI: 10.1128/AAC.38.12.2902. View

Waterer G, Wunderink R, Jones C . Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest. 2000; 118(6):1839-40. DOI: 10.1378/chest.118.6.1839-a. View

Felmingham D, Gruneberg R . The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000; 45(2):191-203. DOI: 10.1093/jac/45.2.191. View

Schmitz F, Boos M, Mayer S, Verhoef J, Milatovic D, Fluit A . In vitro activity of faropenem and 21 other compounds against 385 different genetically characterized isolates of antibiotic-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2001; 48(1):148-52. DOI: 10.1093/jac/48.1.148. View

du Plessis M, Capper T, Klugman K . In vitro activity of faropenem against respiratory pathogens. J Antimicrob Chemother. 2002; 49(3):575-7. DOI: 10.1093/jac/49.3.575. View

Gemmell C . Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother. 2001; 48(1):47-52. DOI: 10.1093/jac/48.1.47. View

Adam D . Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother. 2002; 50 Suppl:1-5. DOI: 10.1093/jac/dkf801. View

Maugein J, Guillemot D, Dupont M, Fosse T, Laurans G, Roussel-Delvallez M . Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in eight French counties. Clin Microbiol Infect. 2003; 9(4):280-8. DOI: 10.1046/j.1469-0691.2003.00520.x. View

Kaplan S, Mason Jr E . Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev. 1998; 11(4):628-44. PMC: 88901. DOI: 10.1128/CMR.11.4.628. View

10.

Metlay J, Hofmann J, Cetron M, Fine M, Farley M, Whitney C . Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000; 30(3):520-8. DOI: 10.1086/313716. View

11.

Woodcock J, Andrews J, Brenwald N, Ashby J, Wise R . The in-vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother. 1997; 39(1):35-43. DOI: 10.1093/jac/39.1.35. View

12.

Lonks J, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen I . Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002; 35(5):556-64. DOI: 10.1086/341978. View

13.

Fine M, Smith M, Carson C, Mutha S, Sankey S, Weissfeld L . Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996; 275(2):134-41. View

14.

Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B . Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis. 2000; 182(3):840-7. DOI: 10.1086/315760. View

15.

von Eiff C, Becker K, Machka K, Stammer H, Peters G . Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001; 344(1):11-6. DOI: 10.1056/NEJM200101043440102. View

16.

Marchese A, Debbia E, Bryskier A, Schito G . Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens. Clin Microbiol Infect. 2002; 5(5):282-287. DOI: 10.1111/j.1469-0691.1999.tb00142.x. View

17.

Jones M, Blosser-Middleton R, Critchley I, Karlowsky J, Thornsberry C, Sahm D . Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents. J Antimicrob Chemother. 2002; 51(1):196-9. DOI: 10.1093/jac/dkg030. View

18.

Turett G, Blum S, Fazal B, Justman J, Telzak E . Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis. 1999; 29(2):321-7. DOI: 10.1086/520209. View

19.

Reinert R, Lutticken R, Lemperle M, Bryskier A . A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 1999; 43 Suppl C:5-8. DOI: 10.1093/jac/43.suppl_3.5. View